Hematopoietic stem cell transplantation will lead leukocyte adhesion deficiency management sales through 2036 with 62.0% of the treatment segment in 2026. The market was valued at USD 9.18 billion in 2025 and grows from USD 9.8 billion in 2026 to USD 18.7 billion by 2036, creating an incremental opportunity of USD 8.94 billion.